High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Researchers writing in the open access journal BMC Cancer studied the pain relieving, anti-inflammatory 'cold laser', finding that it caused increased tumour growth in a mouse model of skin cancer.
Jan M. Bjordal from Bergen University College, Norway worked with a team of Brazilian researchers to carry out the in vitro and in vivo experiments. He said, "LLLT has gained increasing popularity as a treatment for soft tissue injuries and joint conditions. However, there is a shortage of evidence, especially in vivo evidence, about the effects of LLLT in malignant conditions such as melanoma".
Bjordal and his colleagues applied LLLT to cancer cultures and to mice injected with melanoma cells. Although the treatment did not cause any significant changes in the cell cultures, direct irradiation of the tumor with high-dose LLLT caused a significant increase in tumor mass volume and considerable histological alterations, indicating a worsening of the cancer, in the mice. The researchers write, "A high irradiance (2.5W/cm2) combined with high dose of 1050 J/cm2, can stimulate melanoma tumor growth with distinct histological features in vivo".
"It is important that this contraindication is implemented into clinical practice so that LLLT can remain a safe treatment", says Bjordal.
LLLT was pioneered in the 1970s, when it was discovered that light from low-intensity lasers causes cells to proliferate more rapidly. It is marketed as a treatment for hair-loss, pain management, sports medicine and skin care – among many other things. Home-treatment sets are available online for unsupervised use.
Notes to Editors:
1. The effect of low-level laser irradiation (Ga-Al-AsP - 660nm) on in vitro and in vivo melanoma
Lucio Frigo, Juliana SS Luppi, Giovani M Favero, Durvanei A Maria, Socrates C Penna, Jan M Bjordal, Rene J Bensadoun and Rodrigo Alvaro Lopes Martins
BMC Cancer (in press)
During embargo, article available here: http://www.biomedcentral.com/imedia/1951910396243250_article.pdf?random=389799
After the embargo, article available at journal website: http://www.biomedcentral.com/bmccancer/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at email@example.com on the day of publication
2. BMC Cancer is an open access journal publishing original peer-reviewed research articles in all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials. BMC Cancer (ISSN 1471-2407) is indexed/tracked/covered by PubMed, MEDLINE, CAS, EMBASE, Scopus, Current Contents, Thomson Reuters (ISI) and Google Scholar.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.